X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA IPCA LABS SHASUN PHARMA/
IPCA LABS
 
P/E (TTM) x 123.9 41.9 295.7% View Chart
P/BV x 8.5 3.2 265.5% View Chart
Dividend Yield % 0.2 0.2 145.8%  

Financials

 SHASUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
IPCA LABS
Mar-17
SHASUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs94643 14.7%   
Low Rs46503 9.1%   
Sales per share (Unadj.) Rs214.2254.4 84.2%  
Earnings per share (Unadj.) Rs5.316.1 33.2%  
Cash flow per share (Unadj.) Rs15.829.8 53.1%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.2 819.6%  
Book value per share (Unadj.) Rs53.3194.6 27.4%  
Shares outstanding (eoy) m56.62126.20 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.3 14.5%   
Avg P/E ratio x13.135.7 36.7%  
P/CF ratio (eoy) x4.419.2 23.0%  
Price / Book Value ratio x1.32.9 44.5%  
Dividend payout %18.76.2 301.2%   
Avg Mkt Cap Rs m3,95872,300 5.5%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1646,960 31.1%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m12,12732,106 37.8%  
Other income Rs m229226 101.6%   
Total revenues Rs m12,35632,332 38.2%   
Gross profit Rs m1,0094,448 22.7%  
Depreciation Rs m5941,730 34.3%   
Interest Rs m415241 172.4%   
Profit before tax Rs m2302,703 8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73675 -10.8%   
Profit after tax Rs m3022,028 14.9%  
Gross profit margin %8.313.9 60.1%  
Effective tax rate %-31.725.0 -126.7%   
Net profit margin %2.56.3 39.4%  
BALANCE SHEET DATA
Current assets Rs m6,88417,340 39.7%   
Current liabilities Rs m8,4569,559 88.5%   
Net working cap to sales %-13.024.2 -53.5%  
Current ratio x0.81.8 44.9%  
Inventory Days Days62100 61.4%  
Debtors Days Days10857 189.1%  
Net fixed assets Rs m4,97020,779 23.9%   
Share capital Rs m113252 44.9%   
"Free" reserves Rs m2,87524,499 11.7%   
Net worth Rs m3,02024,553 12.3%   
Long term debt Rs m1,8173,517 51.7%   
Total assets Rs m13,34739,595 33.7%  
Interest coverage x1.612.2 12.7%   
Debt to equity ratio x0.60.1 420.0%  
Sales to assets ratio x0.90.8 112.1%   
Return on assets %5.45.7 93.8%  
Return on equity %10.08.3 121.1%  
Return on capital %13.310.5 127.0%  
Exports to sales %46.448.6 95.3%   
Imports to sales %14.214.2 100.1%   
Exports (fob) Rs m5,62215,617 36.0%   
Imports (cif) Rs m1,7284,571 37.8%   
Fx inflow Rs m5,84315,617 37.4%   
Fx outflow Rs m2,1735,828 37.3%   
Net fx Rs m3,6699,790 37.5%   
CASH FLOW
From Operations Rs m3982,764 14.4%  
From Investments Rs m-1,635-1,432 114.2%  
From Financial Activity Rs m1,309-1,591 -82.2%  
Net Cashflow Rs m71-259 -27.5%  

Share Holding

Indian Promoters % 39.2 45.9 85.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.4 31.6%  
FIIs % 17.6 25.3 69.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.4 227.6%  
Shareholders   20,750 36,892 56.2%  
Pledged promoter(s) holding % 12.3 2.1 574.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare SHASUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS